Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director · Chief Financial Officer | August 14, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date August 14, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,956 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 101,010 · Balance 106,956 F1: On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2031-08-14 | Direct | 101,010 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Purchase · Acquired 101,010 · Balance 101,010 F2: The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. F1: On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
F2: The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 14, 2026 23:39 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseWarrants (right to buy) · Derivative | 101,010 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001649989-26-000009 · primary_doc.xml · derivative · entry 2 KENYON LAWRENCE A · CIK 0001230484 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,010 Underlying: Common Stock · 101,010 shares Expires 2031-08-14 F2 · security: The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. F1 · price: On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 23:39 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 101,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001649989-26-000009 · primary_doc.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,956 F1 · price: On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 23:49 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 210,078 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001649989-26-000007 · primary_doc.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,078 Underlying: Common Stock · 210,078 shares Expires 2036-07-21 F1 · derivative.exercise_date: The option was granted to Mr. Kenyon on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Kenyon's continuing service with the Issuer through such vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:53 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,000 | $5.69 | $28,446.00 |
DisclosureSEC source: 0001415889-24-024093 · form4-09302024_080919.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,946 F1 · balance_after: Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:00 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001415889-24-008974 · form4-03222024_050315.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-20 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 23:54 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.83 | $18,300.00 |
DisclosureSEC source: 0001209191-21-027683 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,926 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 22:48 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 3,668,984 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-20-053875 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,668,984 Underlying: Common Stock · 3,668,984 shares Expires 2030-10-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in four equal installments beginning on October 1, 2021 such that the option shall be vested in full on October 1, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:09 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-043224 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in four equal installments beginning on July 17, 2021 such that the option shall be vested in full on July 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 21:55 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 216,435 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-20-020512 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,435 Underlying: Common Stock · 216,435 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in four equal installments beginning on March 19, 2021 such that the option shall be vested in full on March 19, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date, and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| September 18, 2019 Filed Sep 23, 2019 21:09 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | SaleCommon Stock | 1,350 | $1.70 | $2,295.00 |
DisclosureSEC source: 0001209191-19-050468 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,863 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 18, 2019 Filed Oct 15, 2019 21:08 UTC Amendment | Outlook Therapeutics, Inc. OTLK · Entity 608 | SaleCommon Stock | 1,350 | $1.70 | $2,295.00 |
DisclosureSEC source: 0001209191-19-053184 · doc4a.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,926 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 21:04 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001209191-19-049497 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2029-09-12 F1 · derivative.exercise_date: The shares underlying the option shall vest in four equal annual installments beginning on September 12, 2020 such that the option shall be vested in full on September 12, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of a change in control as defined in the Issuer's 2015 Equity Incentive Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 01:24 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-19-011378 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: The shares underlying the option shall vest in four equal installments beginning on February 19, 2020 such that the option shall be vested in full on February 19, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain pre-defined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 01:14 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 25,000 | $0.90 | $22,380.00 |
DisclosureSEC source: 0001209191-19-008782 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,213 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the Reporting Person's sales of shares at $0.89 per share on September 18, 2018 to cover withholding taxes, as reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on September 18, 2018. The Reporting Person has paid to the Issuer $8.19, which represents the full amount of the profit realized in connection with this short-swing transaction, less transaction costs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8823 - $0.8952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 18, 2018 Filed Sep 18, 2018 20:56 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 10,100 | $0.87 | $8,807.20 |
DisclosureSEC source: 0001209191-18-051494 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,213 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.855 - $0.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 21,739 shares of the Issuer's common stock subject to RSUs that will vest on 9/15/2019, subject to continued service through such date. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:09 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-18-045340 · doc4.xml · derivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · Director · CEO, Pres, CFO, Treas & Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-08-01 F1 · derivative.exercise_date: The shares underlying the option shall vest in four equal installments beginning on August 1, 2019 such that the option shall be vested in full on August 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain pre-defined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 22:04 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 26,165 | $1.13 | $29,566.45 |
DisclosureSEC source: 0001209191-17-067229 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,313 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 43,478 shares of the Issuer's common stock subject to RSUs that will vest 50% on each of the third and fourth year anniversaries of the 9/15/15 grant date, subject to continued service through such date. The vesting of RSUs reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on December 22, 2016 was accelerated such that 100% of the shares underling those RSUs vested on December 21, 2017. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 23:07 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156585 · doc4.xml · nonDerivative · entry 1 KENYON LAWRENCE A · CIK 0001230484 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,478 F1 · security: This security represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying this restricted stock unit award vests in two equal installments on each of December 21, 2017 and December 21, 2018, in each case subject to the Reporting Person's continuous service to the Issuer through each such date. In addition, 100% of the shares underlying the restricted stock unit award will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.